The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Anatra
Anas Barbariae · CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE 200 [hp_C]/1 · Tablet · Oral · Anatra LLC
NDC 83641-0001-01 · 30 TABLET in 1 BOTTLE, PLASTIC · UNAPPROVED DRUG OTHER · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Anas Barbariae (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Anatra LLC | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE 200 [hp_C]/1 | Jul 15, 2026 | Sep 2, 2026 |
| TRP Company | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE 200 [hp_C]/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Anatra — NDC 83641-0001-01," retrieved September 3, 2026, https://drugdashboards.com/drug/83641000101.
Free to cite with attribution — see how the data is put together.